Ralliant (NYSE:RAL) Releases Q3 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its third quarter 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.720-0.780 for the period, compared to the consensus earnings per share estimate of 0.680. The company issued revenue guidance of $570.0 million-$590.0 million, compared to the consensus revenue estimate of $556.4 million. Ralliant also updated its FY 2026 guidance to 2.760-2.900 EPS.

Analysts Set New Price Targets

Several research firms recently issued reports on RAL. Citigroup increased their price target on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, July 26th. Evercore initiated coverage on Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price for the company. Royal Bank Of Canada raised their target price on Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a research report on Friday. Finally, TD Cowen upped their price target on Ralliant from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Price Performance

Shares of Ralliant stock opened at $65.78 on Friday. The stock has a market capitalization of $7.36 billion and a price-to-earnings ratio of -6.06. The firm’s 50-day moving average price is $67.20 and its two-hundred day moving average price is $54.34. The company has a current ratio of 1.52, a quick ratio of 1.05 and a debt-to-equity ratio of 0.75. Ralliant has a 1-year low of $37.27 and a 1-year high of $75.41.

Ralliant (NYSE:RAL) last posted its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million during the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts predict that Ralliant will post 2.83 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were given a $0.05 dividend. The ex-dividend date was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is presently -1.83%.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
• Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
• Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
• Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
• Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RAL. Dodge & Cox grew its holdings in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Ralliant in the second quarter worth about $257,200,000. State Street Corp bought a new position in shares of Ralliant in the second quarter worth about $213,096,000. Invesco Ltd. lifted its position in shares of Ralliant by 4.9% during the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock worth $206,674,000 after purchasing an additional 187,898 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Ralliant by 19.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,423,268 shares of the company’s stock worth $174,279,000 after purchasing an additional 563,822 shares in the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.